0000000000003135

AUTHOR

Angela Ciancio

showing 4 related works from this author

Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspi…

2009

The prognosis for thalassemia major has dramatically improved in the last two decades. However, many transfusion-dependent patients continue to develop progressive accumulation of iron. This can lead to tissue damage and eventually death, particularly from cardiac disease. Previous studies that investigated iron chelation treatments, including retrospective and prospective non-randomised clinical trials, suggested that mortality, due mainly to cardiac damage, was reduced or completely absent in patients treated with deferiprone (DFP) alone or a combined deferiprone-deferoxamine (DFP-DFO) chelation treatment. However, no survival analysis has been reported for a long-term randomised control …

MaleThalassemiaKaplan-Meier Estimatelaw.inventionchemistry.chemical_compoundRandomized controlled triallawCause of DeathNeoplasmsDeferiproneProspective StudiesChildCause of deathHazard ratioHematologyMiddle AgedCombined Modality TherapySurvival RateThalassemia survival chelation treatment trial thalassemia majorCombinationSplenectomyMolecular MedicineDrug Therapy CombinationFemaleDeferiproneAdultmedicine.medical_specialtyAdolescentPyridonesDeferoxamineIron Chelating AgentsYoung AdultDrug TherapyInternal medicinemedicineHumansBlood TransfusionAdolescent; Adult; Blood Transfusion; Cause of Death; Chelation Therapy; Child; Combined Modality Therapy; Deferoxamine; Drug Therapy; Combination; Female; Heart Failure; Humans; Iron Chelating Agents; Kaplan-Meiers Estimate; Male; Middle Aged; Neoplasms; Proportional Hazards Models; Prospective Studies; Pyridones; Splenectomy; Survival Rate; Young Adult; beta-ThalassemiaMolecular BiologySurvival rateKaplan-Meiers EstimateSurvival analysisProportional Hazards ModelsHeart Failurebusiness.industryProportional hazards modelbeta-ThalassemiaCell Biologymedicine.diseaseChelation TherapySurgerychemistrybusiness
researchProduct

Long-Term Use of Deferiprone Enhances Significantly the Left Ventricular Ejection Function in Thalassemia Major

2011

Abstract Abstract 5302 Background: A multicentre randomized controlled trial (RCT) was designed to assess the effectiveness of long-term sequential deferiprone-deferoxamine (DFO-DFP) versus DFP alone to treat thalassaemia major (TM) (Maggio et al.,2009). Effectviness, survival, adverse events and costs were comparable between the groups. These findings were confirmed in a further 21-month follow-up (Pantalone et al., 2011). Moreover, deferiprone-alone has been reported to be superior to deferoxamine for the removal of cardiac iron and improvement in left ventricular ejection function (LVEF). However, little is known of its relative effect on LVEF after long-term treatment. Therefore, data f…

medicine.medical_specialtyEjection fractionbusiness.industryThalassemiaImmunologyDeferasiroxRetrospective cohort studyCell BiologyHematologymedicine.diseaseBiochemistrylaw.inventionchemistry.chemical_compoundchemistryRandomized controlled triallawHeart failureInternal medicinemedicineCardiologybusinessDeferiproneSurvival analysismedicine.drugBlood
researchProduct

Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major

2013

Transfusion and iron chelation treatment have significantly reduced morbidity and improved survival of patients with thalassemia major. However, cardiac disease continues to be the most common cause of death. We report the left-ventricular ejection fraction, determined by echocardiography, in one hundred sixtyeight patients with thalassemia major followed for at least 5 years who received continuous monotherapy with deferoxamine (N = 108) or deferiprone (N = 60). The statistical analysis, using the generalized estimating equations model, indicated that the group treated with deferiprone had a significantly better left-ventricular ejection fraction than did those treated with deferoxamine (c…

AdultMalemedicine.medical_specialtyIron OverloadHeart DiseasesPyridonesThalassemiaDeferoxamineIron Chelating AgentsVentricular Function Leftlaw.inventionYoung Adultchemistry.chemical_compoundRandomized controlled triallawInternal medicineHumansMedicineDeferiproneIn patientYoung adultMolecular BiologyThalassemia major Left ventricular ejection fraction (LVEF) Deferiprone Deferoxamine Echocardiography ChelationRetrospective StudiesEjection fractionbusiness.industrybeta-ThalassemiaStroke VolumeRetrospective cohort studyCell BiologyHematologymedicine.diseaseDeferoxamineTreatment OutcomechemistryCardiologyMolecular MedicineFemalebusinessDeferipronemedicine.drug
researchProduct

Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients

2012

A multicenter randomized open-label long-term sequential deferiprone–deferoxamine (DFP-DFO) versus DFP alone trial (sequential DFP-DFO) performed in patients with thalassemia major (TM) was retrospectively reanalyzed to assess the variation in the left ventricular ejection fraction (LVEF) [1].

AdultMalemedicine.medical_specialtyTime FactorsPyridonesHeart VentriclesThalassemiaDeferoxamineIron Chelating AgentsModels BiologicalDrug Administration Schedulechemistry.chemical_compoundInternal medicineHumansMedicineLeft ventricular ejectionDeferiproneIn patientRetrospective StudiesUltrasonographyEjection fractionbusiness.industrybeta-ThalassemiaStroke VolumeHematologymedicine.diseasehumanitieschemistryCardiologyDrug Therapy CombinationFemaleThalassemia major Left ventricular ejection fraction Deferiprone sequential deferiprone-deferoxamine Echocardiography ChelationbusinessDeferiproneAmerican Journal of Hematology
researchProduct